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ABSTRACT: The synthetic flexibility of metal-organic frameworks (MOFs) with high loading capacities and biocompat-
ibility makes them ideal candidates for drug delivery system (DDS). Here, we report the use of CAU-7, a biocompatible 
bismuth-based MOF, for the delivery of two cancer drugs, sodium dichloroacetate (DCA) and α-cyano-4-hy-
droxycinnamic acid (α-CHC). We achieved loadings of 33 and 9 wt.% for DCA and α-CHC, respectively. Interestingly, 
CAU-7 showed a gradual release of the drugs, achieving time release up to 17 days for DCA and 31 days for α-CHC. We 
then performed mechanical and thermal amorphization processes to attempt to delay even more the delivery of guest 
molecules. With the thermal-treatment, we were able to achieve an outstanding 32% slower release of α-CHC from the 
thermal treated CAU-7. Using in vitro studies and endocytosis inhibitors, confocal microscopy and fluorescence-acti-
vated cell sorting (FACS), we also demonstrated that CAU-7 was successfully internalized by cancer cells, partially avoid-
ing lysosome degradation. Finally, we showed that CAU-7 loaded either with DCA or α-CHC had a higher therapeutic 
efficiency compared with the free drug approach, making CAU-7 a great option for biomedical application.                    
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INTRODUCTION 
Conventional pharmaceutical formulations are character-
ized by a number of drawbacks such as drug-limited sol-
ubility, drug degradation before reaching the desired or-
gan, lack of selectivity, poor distribution, and undesired 
pharmacokinetics.1–3  Very often, free drugs need to circu-
late in the blood stream at high concentrations in order to 
reach a specific organ or tissue at the desired concentra-
tion, and this condition may generate healthy tissue dam-
age. By using a drug delivery systems (DDSs), it is possi-
ble to overcome the side effects of free drugs,1,2 achieving 
a controlled release, improving drug solubility issues, 
conferring protection from degradation and accomplish-
ing, potentially, a targeted delivery.4–6 
In the last years, metal-organic frameworks (MOFs) 
have been widely studied for drug delivery and biosens-
ing applications.7,8 MOFs are hybrid ordered porous ma-
terials made from metal centers connected through or-
ganic linkers, offering exceptionally high apparent sur-
face areas (up to 8,000 m2/g).9,10 One of the main ad-
vantages of MOFs over organic (e.g. liposomes, micelles) 
and inorganic (e.g. zeolites, mesoporous silica) systems is 
their high loading capacities, with values as high as 2 g of 
drug per g of solid.11 In addition, MOF synthetic flexibility 
offers the possibility for tuning their pore properties and 
adsorption performance by changing the individual 
building blocks, i.e. the metal clusters and organic linkers 
that conform them, to provide the desired properties.11,12 
The almost infinite possible combinations for designing 
new MOFs with different chemical properties, topologies, 
pore sizes and shapes,8,9,12,13 has allowed an amazing 
growth in this field, with more than 90,000 different struc-
tures reported so far.14–17 
When proposing MOFs for biomedical applications, 
they require high biocompatibility and low accumulation 
in cells. The vast number of MOFs allows one to select op-
timal building blocks, including metals. This includes not 
only an optimal MOF-drug interaction and loading ca-
pacity, but also biocompatible building blocks, as well as 
an adequate particle size and external surface chemistry 
that allows a more efficient endocytosis process.18,19 In the 
past, one of the most critical limitations in the applicabil-
ity of MOFs in industry has been the general lack of long-
term chemical stability. However, in biomedical applica-
tions and specifically in drug delivery, their moderately 
low aqueous stability is beneficial, so MOF particles can 
be biodegraded and eliminated from the body after the 
 
drug is released, preventing detrimental accumulation in 
vivo. Eventually, biocompatible MOFs offer high loading 
capacities, controlled drug-release, can overcome drug 
solubility issues and can confer drug protection from deg-
radation.4–6 In the past years, Horcajada and co-workers 
pioneered these studies working on the loading of diverse 
anticancer agents and also investigated the potential of 
post-synthetic modifications for improving their biologi-
cal properties.20–24 Morris and co-workers have greatly 
contributed in the topical formulation using MOFs, fo-
cused on the delivery of nitric oxide (NO) for its use as 
antithrombotic agent.25 Mirkin and co-workers reported 
the first covalently functionalized MOF-oligonucleotide 
(DNA) conjugated oriented to facilitate the cellular up-
take,26 whereas Wang and co-workers worked on the de-
livery of DNAzymes, single-stranded DNA molecules 
known as potent therapeutic agents for gene therapy, 
achieving an efficient delivery without degradation into 
cancer cells.27 
Despite the success of MOFs, their relatively poor 
chemical stability of the MOF family jeopardies many of 
their advantages for industrial applications. Such chemi-
cal instability can be considered advantageous in drug 
delivery processes, since, unlike e.g. mesoporous silicas, 
MOF DDS can be easily biodegraded in the body after the 
drug has been released. One of their principal current lim-
itations as DDS is the fast kinetic drug release during the 
desorption process – typically below 48 h.20 We addressed 
this problem through different strategies: using a post-
loading mechanical amorphization, and observing a sus-
tained drug release of more than 30 days;28 enhancing the 
therapeutic effect of a cancer drug using large-pore 
MOFs;29 as well as using a polyethylene glycol coating, re-
leasing only ca. 40% of the cargo after 5 days, while keep-
ing the remaining amount encapsulated inside the MOF.30 
To the best of our knowledge, such extremely long release 
times have not been reported before for any MOF or DDS 
with similar characteristics. For instance, it has been pos-
sible to extend the release time of a water-soluble drug up 
to 5 days using a core–shell microsphere and core–shell 
biodegradable microfibers with a diameter of ca. 400 
µm.31,32 Also, hydrogel microspheres of 3–5 µm of diame-
ter showed release time prolonged for 13 days. However, 
when using larger hydrogel cylinders, drug release was 
increased up to 200 days.33 All these systems are useful 
options only in the case of cell membrane permeable 
drugs and non-parenteral routes of administration. This 
is because, in contrast with our proposed amMOF system, 
the size of the carriers is not small enough (i.e. ∼200 nm) 
to be endocytosed by cells or to circulate through the 
smallest capillaries. 
In addition to the wealth of different cargoes and tun-
ing possibilities that MOFs offer, understanding the cel-
lular uptake mechanisms for them is a critical aspect in 
drug delivery. We recently investigated the role of the 
particle size19 and surface chemistry18,30 on the internaliza-
tion pathways and intracellular final fate of Zr-based 
MOFs, eventually allowing to change the efficacy of the 
MOFs as DDSs. Three endocytic pathways are the most 
common: clathrin- and caveloae-mediated endocytosis 
and macropinocytosis.34,35 Particles internalized through 
endocytosis enter cells entrapped in vesicles called endo-
somes. Endosomes formed by clathrin-mediated endocy-
tosis and macropinocytosis become mature vesicles or 
late endosomes that fuse with lysosomes, leading to the 
degradation of the drug delivery system and the loaded 
cargo, consequently diminishing or totally voiding its 
therapeutic effect.36 On the other hand, particles internal-
ized via caveolae-mediated endocytosis can later be trans-
ported to diverse location in cells. Interestingly, these par-
ticles can be delivered to a final intracellular location 
avoiding the lysosomal degradation.37–39 eventually, to 
comprehensively design efficient DDS based on MOFs, it 
is important to not only have biocompatible systems, but 
also have a system able to avoid the lysosomal degrada-
tion. 
In this work, we studied a bismuth-based MOF, CAU-
740 ([Bi(BTB)], with BTB3- = 1,3,5-benzenetrisbenzoate and 
CAU standing for Christian- Albrechts-Universität), as a 
DDS. Despite the fact that bismuth presents low toxicity 
– being used broadly in medicine and veterinary prac-
tice41,42 – to the best of our knowledge, no previous studies 
have used it for drug delivery. We loaded CAU-7 with the 
cancer drugs sodium dichloroacetate (DCA) and α-cyano-
4-hydroxycinnamic acid (α-CHC), both capable of modi-
fying cancer metabolic pathways.43–46 DCA is involved in 
restoring the normal metabolic respiration in the mito-
chondria – lost in cancer cells – and therefore inducing 
apoptosis.47 The abnormal glucose metabolism and re-
duced mitochondrial oxidation of tumor cells is indeed an 
enormous advantage for them as it contributes to tumor 
growth independently of the oxygen present.48 On the 
other hand, α-CHC has the ability to inhibit the protein 
monocarboxylate transporter 1 (MCT1), upregulated in 
diverse types of cancer.45,49 We used a complete combina-
tion of in vitro studies, confocal microscopy, fluorescence-
activated cell sorting (FACS) and Monte Carlo simula-
tions to confirm the successful incorporation of CAU-7 
into the cells and to understand the cellular uptake mech-
anism for CAU-7 internalization. 
RESULTS AND DISCUSSION 
STABILITY AND BIOCOMPATIBILITY OF CAU-7 
CAU-7 forms trigonal prismatic particles and the frame-
work structure is composed of Bi3+ ions and BTB3- linker 
molecules (BTB3- = 1,3,5-benzenetrisbenzoate); the Bi3+ 
ions are nine-fold coordinated by oxygen atoms of the 
BTB3- ions (Figure S1). The BTB3- linker molecules build 
 
the wall of a honeycomb network with approximately 10 
Å wide and one-dimensional channels (SBET = 1150 m2g-1, 
Vp = 0.43 cm3g-1).40 We selected a bismuth-based MOF due 
to its biocompatibility, already established in the medici-
nal and cosmetic chemistry. For example, the well-known 
bismuth-based Pepto-Bismol™ (bismuth subsalicylate) is 
widely used for stomach disorders,50 bismuth oxychloride 
is used in personal care products and bismuth nitrate is 
used as an antiseptic during surgery.50 The lethal dose 
(LD50) of bismuth oxychloride (BiOCl), 22 g/kg (rat, oral), 
and bismuth oxide, 10 g/kg (mouse, oral), are rather high 
compared to other metals.51 
Figure S2 provides the powder X-ray diffraction (PXRD) 
data of CAU-7, confirming the phase purity of the reac-
tion product; N2 adsorption isotherms confirmed the po-
rosity of nanocrystalline CAU-7 (Figure S3). Figure S4 
shows the scanning electron microscopy (SEM) images of 
the sample, indicating the heterogeneous particle size of 
the MOF, with particle size of around 195±12 nm and 
477±40 nm. Since the tendency of particle aggregation is 
determined by the surrounding media,52 we used dy-
namic light scattering (DLS) to measure the hydrody-
namic diameter (HD) of CAU-7 in growth media and 
phosphate-buffered saline (PBS). Interestingly, the degree 
of aggregation was higher when the MOF particles were 
suspended in PBS (HD = 10,439±1672 nm) compared to 
growth media (HD = 205±3 nm). Arguably, a protein co-
rona formed around the CAU-7 particles through the ad-
sorption of growth media proteins on the external sur-
faceis able to improve its water stability. We analyzed the 
degradation profile of CAU-7 by incubating it in PBS and 
water. Figure 1 shows the release of the organic linker, the 
powder X-ray diffraction (PXRD) patterns and the FTIR 
profiles, demonstrating the higher stability of CAU-7 in 
water compared to PBS. After 13 days, CAU-7 released ca. 
56% and 5% of the linker in PBS and water, respectively, 
whereas 2 days of incubation in PBS is enough to make 
CAU-7 completely amorphous (Figure 1b). After incuba-
tion in PBS, an intense band at around 1000 cm-1, corre-
sponding to PO43-, appeared, while the peaks attributed to 
BTB3- decreased dramatically (band at 1690 cm-1 assigned 
to the C=O stretching vibration of aromatic carboxylic ac-
ids and band ranging from 1605 – 1507 cm-1 assigned to 
C-H and ring C-C stretching vibrations), confirming the 
exchange of the linker by the phosphate (Figure 1c). Since 
phosphate salts are a common electrolyte in the human 
body, one can expect that CAU-7 will degrade in vivo and 
will avoid intracellular accumulation and toxicity. Similar 
degradation effect of PBS has been seen before for Zr-
based MOFs such as UiO-66.53 
Following the degradation studies, we measured the in 
vitro cytotoxicity of CAU-7 and building blocks on HeLa 
cells. Figure 2 shows the MTS viability values for CAU-7,  
 
Figure 1. Stability analysis for CAU-7. a. Degradation pattern 
in PBS (black closed dots) and H2O (red open dots). b. PXRD pat-
terns of calculated CAU-7 (black), as-synthesized (blue) and 
samples incubated for 2 days in PBS (red). c. FTIR analysis 
after PBS exposure for 0 days (black), 2 days (red) and 3 days 
(blue) and H3BTB (green). 
H3BTB and the bismuth salt Bi(NO3)3. The MOF and 
components are biocompatible in the range analyzed, as 
none of the used concentrations exhibited a significate 
difference compared to untreated cells. 






































































































Figure 2. MTS viability assay after 24h on HeLa cells for: a. 
CAU-7, b. H3BTB (black bars) and Bi(NO3)3 (red bars). The er-
ror bars represent the standard combined error of three inde-
pendent samples. 
DRUG ADSORPTION AND ENCAPSULATION ON 
CRYSTALLINE AND AMORPHOUS CAU-7 
After loading DCA and α-CHC into CAU-7 (33.7 and 9.3 
wt.% for DCA and α-CHC, respectively), we confirmed, 
using PXRD, that CAU-7 was able to retain its crystalline 
structure (Figure S5). We also performed Monte Carlo 
simulations to better understand the adsorption of DCA 
and α-CHC in CAU-7. The maximum capacities were pre-
dicted to be 33.3 wt.%  (10.1 mol of drug/mol of CAU-7) 
and 19.9 wt.% (13.7 mol of drug/mol of CAU-7) for DCA 
and α-CHC, respectively, whereas the experimental max-
imum loadings we obtained were of 33.7 wt.%  (9.8 mol 
of DCA/mol of CAU-7)  and 9.3 wt.% (33.2 mol of α-
CHC/mol of CAU-7). Looking at the sizes of both drugs, 
it is clear that DCA was able to diffuse through the pores 
whereas α-CHC showed some issues getting loaded. The 
data also suggests there is space for improvement. Figure 
3 shows snapshots of the adsorption process of these two 
drugs by CAU-7 at low, medium and saturated loadings; 
Figure S6 shows the density distributions during the ad-
sorption process, highlighting the areas where the mole-
cules get adsorbed. DCA and α-CHC are first adsorbed 
on the walls of the MOF structure at low loadings, before 
filling up the whole cavity at higher loadings. 
Figure 4 shows the experimental delivery profiles for 
DCA and α-CHC from CAU-7, exhibiting a two-stage re-
lease (Table S6 shows the fitted equations). In the case of 
DCA, 75% of the release takes place in the first 4 h, 
whereas total release is accomplished at 17 days. A  
similar but slightly slower process is obtained for α-CHC, 
with 65% released in the first 5 h, and total release at 31 
days. The first stage of delivery might be associated with 
desorption of drug molecules weakly adsorbed in center 
of the large pores of CAU-7, as found using GCMC simu-
lations, whereas the second stage may be related with de-
sorption of molecules with a stronger interaction with the 
pores of CAU-7. 
At this point, we then attempted to slow down the re-
lease of the drugs from CAU-7 by inducing an encapsula-
tion of the guest drugs through an amorphization pro-
cess. In the first place, we used a ball-milling, mechanical 
amorphization process on the loaded CAU-7, generating 
the amCAU-7 sample.28,54 Separately, we performed a tem-
perature based amorphization, generating the atCAU-7 
sample, where the fast removal of the solvent from the 
pores provokes the collapse of the framework by the ac-
tion of the internal forces in the liquid-gas meniscus.55 In-
deed, MOFs possessing large pores have been found par-
ticularly susceptible to these issues, presenting  discrep-
ancies between the estimated and  experimental surface 
areas after activation.56 However, from a different point of 
view, solvent removal may be a powerful and useful al-
ternative in order to develop amorphous materials by in-
ducing a framework collapse. PXRD confirms the partial 
structural degradation of both amCAU-7 and atCAU-7 
(Figure S5). 
The drug release profiles differ for both drugs and me-
chanical/temperature amorphization processes. For DCA, 
amCAU-7 reproduces the profile of crystalline CAU-7, 
with a small decrease in the total amount released, 
whereas atCAU-7 releases DCA much faster, with a sin-
gle-step hyperbolic curve and total release at 4 days (see 
Tables S6-S7 for fitting equations). The fast release is 
probably triggered by water molecules dragging DCA 
from the pores during the thermal treatment, possibly 
due to the high loading levels of DCA in the MOF (33 
wt.%) and its small size and high affinity to water. In the 
case of α-CHC, both amCAU-7 and atCAU-7 follow the 
same profile of crystalline CAU-7, but the release was sig-
nificantly slower, in particular for atCAU-7; between 
days0 and 4, the difference in the amount released was 
32% lower from atCAU-7 and 19% for amCAU-7 both com-
pared to crystalline-CAU-7. The slower release from am-
CAU-7 and atCAU-7 would be related to the slow disso-








































Figure 3. Snapshots of DCA (a. to c.) and α-CHC (d. to f.) in 
CAU-7 at different loadings: a. 121 mg.g-1 or 10.8 wt.%, b. 307 
mg.g-1 or 23.5 wt.%, c. saturation with 500 mg.g-1 or 33.3 
wt.%, d. 42 mg.g-1 or 4.0 wt.%, e. 126 mg.g-1 or 11.2 wt.% and 
f. saturation with 248 mg.g-1 or 19.9 wt.%. The drug mole-
cules are represented in green-stick mode.  
 
IN VITRO PERFORMANCE OF CAU-7 
To study the performance of CAU-7 as a DDS for cancer, 
we first confirmed its ability to be internalized by cells. 
Figure 5 shows the confocal microscopy images of HeLa 
cells incubated for 24 h with a CAU-7 sample loaded with 
the hydrophilic and fluorescent molecule calcein 
(cal@CAU-7) as well as with free calcein. Similar to previ-
ous studies, cells treated with only free calcein stained 
weakly and in the form of bright vesicles after 24 h, sug-
gesting the entrapment of dye in endosomes.19,28 On the 
other hand, when using cal@CAU-7 the fluorescent signal 
was significantly stronger. The images are an internal 
plane of cells, allowing the simultaneous visualization of 
the nucleus (blue), cal@CAU-7 (green) and cell membrane 
(red). All this confirms that CAU-7 was effectively inside 
the cells and not attached to the exterior cell membrane. 
We followed the confocal imaging of CAU-7 by investi-
gating the endocytic pathways used by HeLa cells in or-
der to fully understand their internalization and final fate. 
Indeed, the chosen pathway may determine the possible 
scape from lysosomal degradation, making the DDS a 
more efficient system. We used sucrose and chlorproma-
zine endocytosis inhibitors to block clathrin-mediated en 
 
 
Figure 4. Release profile of a. DCA and, b. α-CHC, from crys-
talline CAU-7 (black closed circles), mechanically amor-
phous amCAU-7 (red opened circles), and thermally amor-
phous atCAU-7 (blue closed triangles). Black solid, red dot-
ted and blue dotted lines represent the kinetic of delivery fit-
ting using non-linear regression on crystalline, mechanically 
amorphous and thermally amorphous materials, respec-
tively. 
docytosis, nystatin to inhibit caveolae-mediated endocy-
tosis and rottlerin to inhibit macropinocytosis. Figure 6 
presents the normalized internal fluorescence, using 
Flowcytometry assays (FACS), of HeLa cells after incuba-
tion with the different endocytosis inhibitors. The inter-
nalization of CAU-7 was highly inhibited down to 18% 
after incubation at 4 °C compared to the control at 37 °C, 
confirming that the uptake of CAU-7 occurs through an 
energy dependent process – endocytosis – rather than 
simple diffusion.36,57,58 CAU-7 uptake was also strongly in-
hibited when cells were incubated together with sucrose 
and chlorpromazine, reaching levels of 23 and 47%, re-
spectively. This indicates that both inhibitors affected dif-

















































Figure 5. Confocal microscopy images of HeLa cells incu-
bated with cal@CAU-7 or free calcein for 24 h. 
being considered an inhibitor of clathrin-mediated endo-
cytosis, there is some evidence that it can affect non-clath-
rin-mediated pathways as well.59 For this reason, we used 
chlorpromazine to confirm the result since there is no ev-
idence that it affects caveolae-mediated endocytosis or 
any other pathways.36 On the other hand, when using 
nystatin, internalization levels reduced to 58%; no statis-
tical difference was found when treated with rottlerin. 
This result indicates that the trafficking of CAU-7 is made 
mainly through clathrin- and caveolae- mediated endocy-
tosis, whereas macropinocytosis has a minor effect. Im-
portantly, for particles undergoing caveolae-mediated 
endocytosis it may be possible to partially avoid the lyso-
some compartment and their further degradation – some-
thing critical for DDS design. 
 
Figure 6. Effects of pharmacological endocytosis inhibitors 
on the uptake of cal@CAU-7, measured by FACS. The statis-
tical significance was determined by using ordinary one-way 
ANOVA and is indicated in the graph (**P < 0.01, ***P < 0.001, 
****P < 0.0001). 
We finally determined the performance and cytotoxi-
city of CAU-7 loaded with DCA or α-CHC. Figure 7 
shows the viability of HeLa cells incubated with different 
concentrations. We used an equivalent amount of CAU-7 
for the loaded and empty samples, 0.25, 0.5 and 1 mg/mL, 
in order to allow a useful comparison. In the case of 
DCA@CAU-7, cell viability decreased in 12.5 ± 8, 21.9 ± 5 
and 26.0 ± 5% for the tested concentrations, respectively, 
while free DCA did not have any effects at concentrations 
below 6 mg/mL (Figure S9a). In the case of the higher 
loaded amount, it was observed a statistical difference  
between the DCA loaded MOF and the free molecule. For 
or α-CHC@CAU-7, the effect was lower than for DCA, 
with a reduction on cell viability of 17.0 ± 8.0, 6.8 ± 7.0 and 
17.2 ± 8.0%, whereas free α-CHC did not have any effect 
up to 1 mg/mL (Figure S9b). 
CONCLUSION 
We proposed the use of the bismuth-based MOF CAU-
7 for drug delivery applications. We characterized CAU-
7 and loaded it with the anticancer drugs DCA and α-
CHC, achieving loadings of 33 and 9 wt.%, respectively. 
The moderate stability of CAU-7 in the presence of phos-
phate groups, which can potential prevent its accumula-
tion into cells, combined with an outstanding biocompat-
ibility of the MOF and its building blocks, makes it a 
promising candidate as DDS. CAU-7 exhibited a progres-
sive release of the drugs, with up to 17 days of release for 
DCA and 31 days for α-CHC. Remarkably, after a thermal 
amorphization process of CAU-7, a 32% slower release of 
α-CHC was successfully achieved. We demonstrated that 
CAU-7 was efficiently internalized by HeLa cells. Since 















































Figure 7. MTS assay after 24h of a) DCA@CAU-7, and b) α-
CHC@CAU-7. * indicates P ≤ 0.05 in comparison with the 
empty MOF (Student’s test). Black bars correspond to empty 
material and white ones to loaded CAU-7. 
through caveolae-mediated endocytosis, they can poten-
tially avoid the lysosomes without undermining the ther-
apeutic effect of the DDS, making CAU-7 even more in-
teresting for biomedical applications. All in all, we 
showed loaded CAU-7 presented an improved perfor-
mance compared with free drug formulations. 
EXPERIMENTAL SECTION 
Materials: Bi(NO3)3·5H2O, DMF and H3BTB were bought from 
Alfa Aesar, Grüssing and BASF, respectively. Methanol (99.9%), 
nystatin, sucrose (99.5 %), rottlerin, sodium dichloroacetate 
(DCA, 98%) and α-cyano-4-hydroxycinnamic acid (α-CHC) 
were obtained from Sigma-Aldrich (UK). HeLa cells were ob-
tained from the ATCC. Dulbecco’s modified Eagle’s medium 
(DMEM), fetal bovine serum (FBS), L-glutamine, penicillin, and 
streptomycin were purchased from Invitrogen (UK). Phosphate-
Buffered Saline (PBS) and trypsin–EDTA were purchased from 
Life Technologies™ (UK). The CellTiter 96® Aqueous One Solu-
tion Cell Proliferation Assay (MTS) was obtained from Promega 
(UK). All chemicals and biochemicals used were of analytical 
grade. 
Instruments: All PXRD data were collected in Bragg-Brentano ge-
ometry on a D8 Bruker diffractometer equipped with a primary 
Ge monochromator for Cu Kα1 and a Sol-X solid state detector. 
Collection conditions were: 2-50° in 2θ, 0.02° step size, 15 sec-
onds/step, divergence slits 0.2 mm, receiving slit 0.2 mm. Sam-
ples for SEM were scattered onto spectroscopically-pure carbon 
tabs (TAAB Ltd UK) mounted on aluminium stubs. They were 
coated with 15 nm of gold in a Quorum Emitech K575X sputter 
coater to make them electrically conductive. They were imaged 
in an FEI XL30 FEGSEM, operated at 5 keV, using an Everhart 
Thornley secondary electron detector. Particle size analysis was 
determined by dynamic light scattering (DLS) with a 
Brookhaven Zeta Plus potential analyzer (detection angle of 90° 
and a 35 mW laser). The measurements were performed in phos-
phate-buffered saline (PBS) and growth media at room temper-
ature. Thermogravimetric analysis (TGA) was performed using 
a TA Instruments Q-500 series thermal gravimetric analyzer, 
with the sample (0.7 - 2 mg) held on a platinum pan under a con-
tinuous flow of dry N2 gas. TGA curves were obtained using a 
heating rate of 5 °C/min and up to 600 °C. The FTIR spectra were 
recorded in the range 4000-500 cm-1 on an FTIR spectrometer 
(Perkin Elmer, Spectrum Two). N2 sorption isotherms were rec-
orded at 77 K on a BELsorp max. Samples were activated under 
reduced pressure at 150 °C for 12 h. The BET area was deter-
mined using the Rouquerol consistency criteria;60 the micropore 
volume was calculated at p/p0 = 0.9. 
Synthesis: In literature, the synthesis conditions of CAU-7 were 
optimized to form microcrystalline particles.40 Thus, for medical 
applications the synthesis conditions were optimised to form 
nanocrystalline particles. CAU-7 synthesis was carried out un-
der solvothermal conditions in a Biotage Initiator microwave 
oven. Briefly, 20 mL MeOH were added to a mixture of 1,3,5-
benzenetrisbenzoic acid (H3BTB, 200 mg, 456 µmol) and ground 
Bi(NO3)3·5 H2O (148.3 mg, 306 µmol) in a 30 mL glass vial. The 
sealed vial was shaken and heated in a microwave assisted syn-
thesis to 120 °C for 20 min under stirring with 900 rpm. The solid 
product was filtered off and washed with MeOH, DMF and 
MeOH again. A yellow powder was obtained in a yield of 151.6 
mg (52% based on H3BTB). The synthesis was repeated 8 times 
and all products were mixed into one batch after characteriza-
tion with PXRD. For activation, the sample was heated at 150 °C 
for 5 h. 
Stability: H3BTB release experiments were performed in an incu-
bator at 37 °C with orbital agitation and using phosphate buff-
ered saline (PBS) at pH 7.4 in order to simulate physiological 
conditions. 5 mg of empty CAU-7 was placed into a dialysis bag 
(MWCO 3500, molecular weight cut-off Da, Medicell Interna-
tional) with a total volume of 10 mL of PBS. At different times, 1 
mL of PBS was taken and replaced with 1 mL of fresh PBS. The 
amount of linker released was measured by using a UV-vis spec-
trophotometer at 272 nm. The corrected concentration of H3BTB 
release is given by the equation [1]:  
ct =c't + 
v
V

































































where ct is the corrected H3BTB concentration at time t, c’t is the 
apparent H3BTB concentration, v is the sample taken and V is the 
total volume of the solution. Every experiment was performed 
by triplicate. 
Drug loading experiments: DCA adsorption was performed by 
soaking 250 mg of activated MOF into 5 mL of a methanolic DCA 
solution (2 M) at room temperature under stirring for 3 days. The 
α-CHC loading was achieved by soaking 250 mg of solids in 25 
mL of a methanolic α-CHC solution (10 mg/mL) at room tem-
perature under stirring. In both cases, the loaded CAU-7 sam-
ples were collected by centrifugation at 5500 rpm for 20 minutes, 
washed twice with methanol, centrifuged again for 10 minutes 
and dried overnight at 80 °C to remove the solvent. The amount 
of DCA adsorbed was quantified by using oxygen flask combus-
tion technique to burn the samples and collect the chloride pre-
sent, coming from DCA. The chloride then was titrated in a Ra-
diometer TTT85 auto titrator. The amount of α-CHC was quan-
tified using TGA measurements. 
Mechanical amorphization: 0.1 g of drug loaded CAU-7 was placed 
in a stainless steel jar along with an 8 mm stainless steel ball. The 
jar was then oscillated at 20 Hz for 30 minutes using a Retsch 
MM200 mill resulting in amorphous loaded MOF. 
Thermal amorphization: 40 mg of drug loaded CAU-7 was placed 
in a glass vial with a small amount of water, enough to get the 
solids wet. Then, the sample was heated at 180°C for 5 h. 
Delivery: DCA and α-CHC release experiments were performed 
in an incubator at 37 °C with orbital agitation and using PBS at 
pH 7.4 in order to simulate physiological conditions. 20 mg of 
DCA loaded CAU-7 or 5 mg of α-CHC loaded CAU-7 (crystal-
line, mechanically or thermally amorphous) were placed into a 
dialysis bag (MWCO 3500, molecular weight cut-off Da, Medi-
cell International) with a total volume of 10 mL of PBS. At differ-
ent times, 1 ml of PBS was taken and replaced with 1 ml of fresh 
PBS. The amount of α-CHC released was measured by using a 
UV-vis spectrophotometer at 337 nm. The corrected concentra-
tion of α-CHC release is given by the equation [1]. The amount 
of DCA released was determined by High Pressure Liquid Chro-
matography (HPLC). We used a Hewlett Packard 1050 HPLC 
system supplied with a UV-detector and a SphereClone SAX col-
umn (5 µm, 4.6x150 mm, Phenomenex). The mobile phase con-
sisted of 10 % Acetonitrile (v/v) and 90 % (v/v) potassium phos-
phate buffer 200 mM, pH 6.0. The flow rate was set at 1 mL/min 
and the injection volume was 50 µL. The detection of DCA was 
set at 222 nm and the retention time of DCA was around 1 min. 
The calibration curve of DCA was prepare in methanol using 
different concentrations from 0 to 100 µg/mL. 
Cell culture: HeLa cells were maintained at 37 °C with 5% CO2 in 
high rich glucose (4500 mg/L) Dulbecco's modified Eagle's Me-
dium (DMEM) supplemented with 10% (v/v) Fetal Bovine Se-
rum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 
μg/mL streptomycin. The cells were passaged three times a week 
(at 75-80% of confluence) at a density of 2.8 x 104 cells/cm2. 
Cytotoxicity assay: the cytotoxicity activity of DCA and α-CHC as 
well as, empty and loaded CAU-7, was investigated using the 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy- phenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) (Promega, UK) reduction 
assay. The day before the experiment, the cells were seeded into 
a 96-well-plate at a density of 5 x 103 cells per well. Prior to the 
treatments, the cells were washed twice with PBS. The different 
amounts of MOF and α-CHC were dispersed in cell culture me-
dia. Then they were added to the cells and incubated for 24 h at 
37 °C with 5% CO2. To measure the toxicity, the cells were 
washed extensively to remove the solids, the media was re-
placed with 100 l of fresh culture media containing 20 l of 
MTS/phenazine methosulfate (in a proportion 20:1) solution and 
the plate was incubated for 1 h and 15 min at 37ºC with 5% CO2. 
The plates were then read by UV/Vis spectroscopy at 490 nm. 
Confocal microscopy: HeLa cells were seeded in a NUNCTM imag-
ing four-well-plate at a density of 1.11 x 105 cells/mL and incu-
bated for 24 h at 37 ºC with 5% CO2 in DMEM supplemented 
with 10% (v/v) Fetal Bovine Serum (FBS), 2 mM L-glutamine, 100 
units/mL penicillin and 100 μg/mL streptomycin. The cells were 
then washed twice with PBS and incubated together with 0.5 
mg/mL of cal@CAU-7 for 24 h. The MOFs were well dispersed 
in the culture media before being added to the well plates con-
taining the cells. Untreated cells and free calcein (0.056 mg/ml) 
were included as controls. After the incubation time, cells were 
washed several times to remove all the non-internalized parti-
cles. Cells were then incubated for 15 min with 5 g/ml of 
Hoechst 33342 (H33342) and 1X of CellMask™ Orange to stain 
the nucleus and cell membrane, respectively. Cells were then 
washed extensively to remove the dyes and fresh media without 
phenol red was added to each sample. Finally, the four-well 
plate was placed on a Leica TCS SP5 confocal microscope to be 
imaged. The microscope was equipped with 405 diode, argon 
and HeNe lasers. Leica LAS AF software was used to analyze the 
images. 
Flow cytometry assays (FACS): In FACS experiments, the media of 
each well was aspirated and the wells were washed extensively. 
The cells were then harvested by adding 0.1 mL of trypsin and 
incubated for 5 min at 37 ºC with 5 % CO2. The cells were recov-
ered by centrifugation, 5 min at 1200 rpm, and re-suspended in 
100 μl of cDMEM without addition of phenol red. Finally, the 
samples were measure in a Cytek DxP8 analyzer cytometer 
within 30 min. The analysis of the data was done using FlowJo 
and Prism software. 
Treatment with inhibitors: HeLa cells were seeded in a Cellstar 24-
well plate at a density of 5 x 104 cells/well and incubated for 48 h 
at 37 ºC with 5 % CO2 in cDMEM. Then, each well was washed 
with PBS and pre-treated either at 4 °C or with sucrose (102.7 
mg/mL, 0.3 M), chlorpromazine (31.9 μg/mL, 100 μM), nystatin 
(250 μg/mL), and rottlerin (2.6 μg/mL, 5 μM) for 30 min at 37 ºC. 
Subsequently, cal@CAU-7 was added and incubated for another 
1.5 h., time enough to allow endocytosis processes to take place 
and avoid the activation of uptake compensatory mechanisms.36 
Subsequently, samples were measured by flow cytometry. The 
independent values were normalized against the positive con-
trol without the addition of inhibitors at 37 °C. 
Computational methods: We performed grand canonical Monte 
Carlo (GCMC) simulations of DCA and α-CHC in CAU-7 at 
body temperature 310 K with the multi-purpose code RASPA61 
to obtain snapshots of the saturated state of the drugs in CAU-7. 
The simulations were performed in the NVT ensemble to obtain 
snapshots of the drugs in CAU-7 at low and medium loadings. 
We used an atomistic model of CAU-7 for which the framework 
atoms were kept fixed at the crystallographic positions. We used 
the standard Lennard-Jones (LJ) 12-6 potential to model the Van 
der Waals interactions, using Lorentz-Berthelot mixing rules to 
 
define the interactions between the framework and adsorbate at-
oms, and a Coulomb potential to describe the electrostatic inter-
actions. The parameters for the framework atoms were derived 
from the Universal Force Field62 and the Dreiding Force Field,63 
whereas DCA and α-CHC were modelled with GAFF4RASPA 
using the general AMBER potential (Table S2).64 EQeq was used 
to assign the partial charges of the framework. LJ interactions 
beyond 12.8 Å were neglected. The Ewald sum method was used 
to compute the electrostatic interactions in the system. Up to 
500,000 Monte Carlo cycles were performed, the first 50% of 
which were used for equilibration, and the remaining steps were 
used to calculate the ensemble averages. Monte Carlo moves 
consisted of insertions, deletions, displacements, and rotations. 
In a cycle, N Monte Carlo moves are attempted, where N is de-
fined as the maximum of 20 or the number of adsorbates in the 
system.  
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